How were LogicBio Therapeutics' earnings last quarter?

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) announced its earnings results on Monday, November, 15th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.01. The company earned $2.12 million during the quarter, compared to analyst estimates of $5.02 million. LogicBio Therapeutics had a negative trailing twelve-month return on equity of 115.29% and a negative net margin of 246.71%.

What other stocks do shareholders of LogicBio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT) , Alector (ALEC) , Gossamer Bio (GOSS) , Kaleido Biosciences (KLDO) , Acceleron Pharma (XLRN) , Stoke Therapeutics (STOK) , Precision BioSciences (DTIL) , Micron Technology (MU) , Homology Medicines (FIXX) and II-VI (IIVI) .

When did LogicBio Therapeutics IPO?

LogicBio Therapeutics (LOGC) raised $77 million in an initial public offering (IPO) on Friday, October 19th 2018. The company issued 5,800,000 shares at $12.50-$14.00 per share. Jefferies, Barclays and William Blair served as the underwriters for the IPO and Chardan was co-manager.

NASDAQ:LOGC

LogicBio Therapeutics (LOGC) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free LOGC Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $2.07
▼
$2.07
50-Day Range: $2.04
▼
$2.07
52-Week Range: $0.26
▼
$3.77

Volume: N/A
Average Volume: 652,526 shs
Market Capitalization: $68.23 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get LogicBio Therapeutics alerts:

Ad TradeSmith

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

About LogicBio Therapeutics Stock (NASDAQ:LOGC)

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Ad TradeSmith

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

LOGC Stock News Headlines

March 27, 2024 | seekingalpha.com

RVVTF Revive Therapeutics Ltd.

September 24, 2023 | finance.yahoo.com

LogicBio's IPO: What You Need To Know

April 19, 2024 | TradeSmith (Ad)

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

March 31, 2023 | uk.finance.yahoo.com

Rare Diseases Market is projected to grow at a CAGR of 12.27% by 2033: Visiongain Reports Ltd

November 16, 2022 | finance.yahoo.com

Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics

November 14, 2022 | finanznachrichten.de

LogicBio Therapeutics, Inc.: LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 14, 2022 | finance.yahoo.com

LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 7, 2022 | benzinga.com

Short Volatility Alert: LogicBio Therapeutics, Inc.

April 19, 2024 | TradeSmith (Ad)

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

October 17, 2022 | marketwatch.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOGC, IMRA, SBTX

October 4, 2022 | benzinga.com

INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of LogicBio Therapeutics, Inc. - LOGC

October 3, 2022 | msn.com

Looking Into LogicBio Therapeutics's Recent Short Interest

October 3, 2022 | marketwatch.com

LogicBio Therapeutics Shares Soar on Takeover by AstraZeneca >LOGC

October 3, 2022 | bizjournals.com

AstraZeneca acquires local startup at 660% premium

October 3, 2022 | finance.yahoo.com

LogicBio's stock skyrockets after buyout bid for a 667% premium

October 3, 2022 | msn.com

AstraZeneca pays 660% premium for gene therapy firm LogicBio

October 3, 2022 | nasdaq.com

LogicBio To Be Bought By Alexion, AstraZeneca Rare Disease

October 3, 2022 | marketwatch.com

AstraZeneca to Buy LogicBio Therapeutics for $68 Million >LOGC

October 3, 2022 | msn.com

Why LogicBio Therapeutics Stock Is Soaring Today

October 3, 2022 | finance.yahoo.com

Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine

September 21, 2022 | finance.yahoo.com

LogicBio® Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONE

September 1, 2022 | reuters.com

LogicBio Therapeutics Inc

August 18, 2022 | finance.yahoo.com

Earnings Update: LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported And Analysts Are Boosting Their Estimates

August 16, 2022 | benzinga.com

Recap: LogicBio Therapeutics Q2 Earnings

July 27, 2022 | finance.yahoo.com

LogicBio Therapeutics (LOGC) Moves to Buy: Rationale Behind the Upgrade

June 14, 2022 | morningstar.com

LogicBio Therapeutics Inc - Stock Quote LOGC

May 17, 2022 | finance.yahoo.com

LogicBio® Therapeutics to Present at H.C. Wainwright Global Investment Conference

See More Headlines

Receive LOGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:LOGC
CUSIP: N/A
CIK: 1664106
Web: www.logicbio.com
Phone: (617) 245-0399
Fax: N/A
Employees: 62
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.81)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-40,030,000.00
Net Margins: -246.71%
Pretax Margin: -246.71%
Return on Equity: -115.29%
Return on Assets: -53.01%

Debt

Debt-to-Equity Ratio: 0.17
Current Ratio: 1.99
Quick Ratio: 2.26

Sales & Book Value

Annual Sales: $5.41 million
Price / Sales: 12.61
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.48 per share
Price / Book: 4.31

Miscellaneous

Outstanding Shares: 32,963,000
Free Float: 30,293,000
Market Cap: $68.23 million
Optionable: Not Optionable
Beta: 4.61

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Frederic Chereau M.B.A. (Age 55)
Pres, CEO & Director
Comp: $793.2k
Dr. Mark A. Kay M.D. (Age 64)
Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director
Comp: $107.5k
Dr. Daniel J. Gruskin M.D. (Age 50)
Chief Medical Officer
Comp: $577.48k
Dr. Leszek Lisowski M.B.A.
Ph.D., Co-Founder & Member of Scientific Advisory Board
Dr. Adi Barzel Ph.D.
Co-Founder
Mr. Joshua Blacher (Age 49)
Interim CFO, Principal Financial Officer & Principal Accounting Officer
Dr. Matthias Hebben Ph.D.
Global VP & Head of Technology Devel.
Dr. Mariana Nacht Ph.D. (Age 58)
Chief Scientific Officer
Ms. Andrea Paul J.D. (Age 41)
Gen. Counsel & Corp. Sec.
Ms. Grace Lochhead
VP & Head of HR

Key Competitors

View All Competitors

LOGC Stock Analysis - Frequently Asked Questions

How were LogicBio Therapeutics' earnings last quarter?: LogicBio Therapeutics, Inc. (NASDAQ:LOGC) announced its earnings results on Monday, November, 15th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.01. The company earned $2.12 million during the quarter, compared to analyst estimates of $5.02 million. LogicBio Therapeutics had a negative trailing twelve-month return on equity of 115.29% and a negative net margin of 246.71%.
What other stocks do shareholders of LogicBio Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Acceleron Pharma (XLRN), Stoke Therapeutics (STOK), Precision BioSciences (DTIL), Micron Technology (MU), Homology Medicines (FIXX) and II-VI (IIVI).
When did LogicBio Therapeutics IPO?: LogicBio Therapeutics (LOGC) raised $77 million in an initial public offering (IPO) on Friday, October 19th 2018. The company issued 5,800,000 shares at $12.50-$14.00 per share. Jefferies, Barclays and William Blair served as the underwriters for the IPO and Chardan was co-manager.

This page (NASDAQ:LOGC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

LogicBio Therapeutics (LOGC) Stock Price, News & Analysis

About LogicBio Therapeutics Stock (NASDAQ:LOGC)

LOGC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

LOGC Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info